NCT06128824 (HIFI-CAA) is a clinical trial of MR Imaging in Cerebral Amyloid Angiopathy, sponsored by Martin Dichgans.

Who is sponsoring NCT06128824?

NCT06128824 is sponsored by Martin Dichgans.

What drugs are being tested in NCT06128824?

Interventions in NCT06128824: MR Imaging.

What condition does NCT06128824 study?

NCT06128824 studies Cerebral Amyloid Angiopathy.

Is NCT06128824 still recruiting?

NCT06128824 is currently active, enrolled. Last updated 12 September 2025.

Last reviewed 2025-09-12 · How we verify

NCT06128824: HIFI-CAA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High Frequency Imaging in Cerebral Amyloid Angiopathy

Active, enrolled Last updated 12 September 2025

What this trial tests

trial testing MR Imaging in Cerebral Amyloid Angiopathy in 75 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

19 March 2019

Primary endpoint
31 May 2026

31 May 2026

Quick facts

Lead sponsor	Martin Dichgans
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	75
Start date	19 March 2019
Primary completion	31 May 2026
Estimated completion	31 May 2026
Sites	3 locations across Germany

Drugs / interventions tested

MR Imaging

Conditions studied

Cerebral Amyloid Angiopathy — all drugs for Cerebral Amyloid Angiopathy →

Sponsor

Martin Dichgans

Who can join

50 and older, any sex, with Cerebral Amyloid Angiopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cerebral amyloid angiopathy (CAA), caused by amyloid beta depositions in the walls of small cerebral vessels, is remarkably common in the elderly. Its major clinical consequences include intracerebral hemorrhages (ICH) typically in lobar location, functional dependence (disability) and cognitive impairment. Cortical superficial siderosis (cSS) is a common finding in CAA patients and can even be the only magnetic resonance imaging sign of CAA. cSS is of high prognostic relevance regarding future intracerebral haemorrhage and disability. Previous studies suggest that cSS is caused by recurrent focal subarachnoid hemorrhages (fSAH). However, the exact mechanisms and the temporal dynamics of this highly relevant imaging finding are largely unknown. In addition to hemorrhagic manifestations, such as cSS, CAA patients also show ischemic lesions. Of particular interest are acute ischemic lesions as detected by diffusion imaging, which seem to be highly prevalent. Since haemorrhagic and ischemic lesions require fundamentally different therapeutic strategies, understanding the relevance and interplay of both lesion types is highly important for clinical decision making. The HIFI-CAA cohort study aims to provide novel insights into cSS, acute ischemic lesions and other relevant brain alterations in CAA through high-frequency (monthly) serial magnetic resonance imaging.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cerebral amyloid angiopathy: a narrative review.
Noto NM, Speth RC, Robison LS. · · 2025 · cited 4× · PMID 41035821 · DOI 10.3389/fnagi.2025.1632252

Verify or expand the search:

Other trials of MR Imaging

Trials testing the same drug.

NCT06518421 — Emotion and Memory in Chronic Neuropathic Pain · recruiting
NCT03340519 — Early MRI Prediction of Crohns · completed
NCT03218111 — Glymphatic Kinetics In Healthy Adult Volunteers · NA · completed

Other recruiting trials for Cerebral Amyloid Angiopathy

Currently open trials in the same condition.

NCT06933212 — Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy. · recruiting
NCT06393712 — A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy · Phase 2 · recruiting
NCT05734378 — Prognosis of Cerebral Small Vessel Disease · recruiting
NCT04204642 — SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA) · recruiting

Other Martin Dichgans trials

Trials by the same sponsor.

NCT04412187 — Inflammatory faCtors AfteR acUte Ischemic Stroke · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06128824 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Martin Dichgans
Last refreshed: 12 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06128824.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing